BSE Live
Feb 26, 16:01Prev. Close
978.55
Open Price
980.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 26, 15:58Prev. Close
978.20
Open Price
983.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
972.15 (2253)
| Balance Sheet of Natco Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 26.16 | 23.38 | |
| Total Share Capital | 26.16 | 23.38 | |
| Reserves and Surplus | 87.48 | 54.00 | |
| Total Reserves and Surplus | 87.48 | 65.60 | |
| Total Shareholders Funds | 113.65 | 88.98 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 60.89 | 44.37 | |
| Deferred Tax Liabilities [Net] | 19.79 | 18.67 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 80.68 | 63.04 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 50.34 | 61.14 | |
| Trade Payables | 33.86 | 31.57 | |
| Other Current Liabilities | 12.90 | 2.38 | |
| Short Term Provisions | 0.03 | 0.00 | |
| Total Current Liabilities | 97.12 | 95.08 | |
| Total Capital And Liabilities | 291.45 | 247.11 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 96.18 | 96.86 | |
| Intangible Assets | 0.00 | 0.00 | |
| Capital Work-In-Progress | 8.90 | 10.04 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 105.08 | 106.91 | |
| Non-Current Investments | 14.73 | 2.14 | |
| Deferred Tax Assets [Net] | 4.02 | 1.96 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 6.15 | 9.76 | |
| Total Non-Current Assets | 129.97 | 120.76 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 38.00 | 37.58 | |
| Trade Receivables | 33.15 | 47.96 | |
| Cash And Cash Equivalents | 46.33 | 3.25 | |
| Short Term Loans And Advances | 44.00 | 37.54 | |
| OtherCurrentAssets | 0.00 | 0.00 | |
| Total Current Assets | 161.47 | 126.34 | |
| Total Assets | 291.45 | 247.11 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 18.31 | 18.19 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 8.39 | 8.12 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 2.74 | 1.52 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 1.36 | 1.49 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 91.85 | 61.67 | |
| Other Earnings | -- | -- | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 5.81 | 5.81 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | -- | 2.11 | |
| Non-Current Investments Unquoted Book Value | 0.04 | 0.04 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
16.02.2026
Natco Pharma shares rise over 11% after firm receives approval to launch Semaglutide in India
16.02.2026
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
14.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
09.09.2025
Natco Pharma Standalone June 2025 Net Sales at Rs 1,192.70 crore, down 3.57% Y-o-Y